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Background: Resistin, adipocyte-secreting adipokine, may play critical role in modulating cancer pathogenesis. The
aim of this study was to investigate the effects of resistin on HCC adhesion to the endothelium, and the mechanism
underlying these resistin effects.
Methods: Human SK-Hep1 cells were used to study the effect of resistin on intercellular adhesion molecule-1
(ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) expressions as well as NF-κB activation, and hence cell
adhesion to human umbilical vein endothelial cells (HUVECs). 5-Aminoimidazole-4-carboxamide 1-β-D-ribofuranoside
(AICAR), an AMP-activated protein kinase (AMPK) activator, was used to determine the regulatory role of AMPK on
HCC adhesion to the endothelium in regard to the resistin effects.
Results: Treatment with resistin increased the adhesion of SK-Hep1 cells to HUVECs and concomitantly induced
NF-κB activation, as well as ICAM-1 and VCAM-1 expressions in SK-Hep1 cells. Using specific blocking antibodies
and siRNAs, we found that resistin-induced SK-Hep1 cell adhesion to HUVECs was through NF-κB-regulated
ICAM-1 and VCAM-1 expressions. Moreover, treatment with AICAR demonstrated that AMPK activation in SK-Hep1
cells significantly attenuates the resistin effect on SK-Hep1 cell adhesion to HUVECs.
Conclusions: These results clarify the role of resistin in inducing HCC adhesion to the endothelium and
demonstrate the inhibitory effect of AMPK activation under the resistin stimulation. Our findings provide a notion
that resistin play an important role to promote HCC metastasis and implicate AMPK may be a therapeutic target to
against HCC metastasis.
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Vascular cell adhesion molecule-1Background
Hepatocellular carcinoma (HCC), one of the most fre-
quent visceral neoplasms worldwide, is a common fatal
malignant tumor characterized by a high incidence of
recurrence, development of resistance to chemotherapy,
and low sensitivity to radiation therapy [1,2]. HCC is a* Correspondence: wuhsienku@gmail.com
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reproduction in any medium, provided the orprimary malignant cancer of the liver. In spite of many
well-defined risk factors for HCC, including: hepatitis B
and C viral infections, alcoholism and cirrhosis, it has
still been shown that 5 ~ 30% of patients with HCC lack
a readily identifiable risk factor [3,4]. Recently, epidemio-
logical studies have indicated that obesity, especially ab-
dominal obesity, is a new risk factor of HCC [1,5-8].
Adipose tissue is now broadly recognized as an endocrine
organ secreting numerous proteins, also called adipokines,
with both physiological and pathophysiological functions
[3,9]. Resistin is a novel adipocyte-secreting adipokine,
and its activity is implicated in inflammatory processes in-
cluding: atherosclerosis, rheumatic diseases, nonalcoholicd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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evidence indicates that serum resistin is proportionally
related to cancer development, including: breast, gastric,
and colorectal cancers as well as lymphoma. It has also
been suggested that the expression of resistin in cancer
cells is associated with more malignant clinicopathological
processes [1,3,10,11]. However, there is still a lack of infor-
mation about the precise mechanisms of resistin on HCC
development, including adhesion and invasion.
Cancer cell metastasis is a major clinical problem and,
in the case of most cancers, results in a poor prognosis
due to cancer cell development. The maintenance and
promotion of cell adhesion are particularly critical pro-
cesses in cancer cell metastasis. These processes are
modulated by the interaction of cells with one another
and with their microenvironment. Moreover, cell adhe-
sion molecules (CAMs) facilitate these interactions, and
are necessary for all of the metastasis process [12,13].
The intercellular adhesion molecule-1 (ICAM-1) and
vascular cell adhesion molecule-1 (VCAM-1) belong to
the CAM-immunoglobulin (Ig) gene superfamily of ad-
hesion molecules. They can induce the cancer cell adhe-
sion to the endothelium and are also involved in the
immune responses of tumors [14]. The interaction be-
tween ICAM-1/VCAM-1 and their respective ligand
may facilitate the adhesion of cancer cells to the vascular
endothelium, and subsequently aid in the promotion of
metastasis. Resistin has been indicated to induce ICAM-1
and VCAM-1 expressions through transcription factor
NF-κB in endothelial cells and to initiate the cancer cells
and monocyte adhesion [15,16]. However, there is no de-
tailed information about whether resistin induces ICAM-1
and VCAM-1 expressions in cancer cells, and hence
promotes its adhesion and invasion of the endothelium.
An energy imbalance underlies many human meta-
bolic diseases, including obesity and cancer. The AMP-
activated protein kinase (AMPK) is a highly conserved
sensor of cellular energy status and a well-known regula-
tor of cell metabolism [17,18]. It is a heterotrimeric en-
zyme consisting of an α catalytic subunit and non-catalytic
regulatory β and γ subunits. AMPK is activated by a
decrease in the ratio of ATP to AMP, which inhibits
ATP-consuming metabolic pathways and activates the
energy-producing pathways [19]. Recently, AMPK activa-
tion has been demonstrated to play an important role in
regulating cancer development [17-22]. However, the de-
tailed molecular mechanisms between AMPK activation
and cancer metastasis are still controversial, and whether
AMPK activation is a critical controller for HCC adhesion
and subsequent metastasis is unclear.
In the present study, we investigated the regulatory
effects of resistin on HCC adhesion to the endothelium
in human SK-Hep1 cells and the mechanism underlying
these resistin effects. We found resistin-induced SK-Hep1cell adhesion to endothelial cells through transcription
factor NF-κB activation as well as ICAM-1 and VCAM-1
expressions. Moreover, these effects were attenuated by
AMPK activation in SK-Hep1 cells. Our findings provide
new insights into the understanding of resistin-regulated
the adhesion of HCC to the endothelium and the inhibi-
tory effects of AMPK activation.
Methods
Materials
All culture materials were purchased from Gibco (Grand
Island, NY, USA). Recombinant human resistin was pur-
chased from R & D Systems (Minneapolis, MN). Polyclonal
anti-ICAM-1 and anti-VCAM-1 neutralizing antibodies
were obtained from R & D Systems (Minneapolis, MN).
ICAM-1-, VCAM-1-specific siRNA and control siRNA (a
scrambled negative control containing random DNA se-
quences) were purchased from Invitrogen (Carlsbad, CA).
The sequences of ICAM-1- and VCAM-1-specific siRNA
are 5′-CGGCU GGAGC UGUUU GAGAT T-3′ and 5′-
GGAGU GAUUU UUCUA UCGGT T-3′, and 5′-AAUGC
AACUC UCACC UUAAT T-3′ and 5′-UUAAG GUGAG
AGUUG CAUUT T-3′, respectively. Pyrrolidine dithio-
carbamate (PDTC, NF-κB inhibitor), SN50, AICAR and
all other chemicals of a reagent grade were obtained
from Sigma (St. Louis, MO).
Cell culture
The HCC SK-Hep1 cells were purchased from the Bior-
esources Collection and Research Center (BCRC) of
the Food Industry Research and Development Institute
(Hsinchu, Taiwan). Cells were maintained in Dulbecco’s
Modified Eagle Medium (DMEM) supplemented with 10%
fetal bovine serum (FBS) and 1% penicillin/streptomycin
in a CO2 incubator at 37°C.
Human umbilical vein endothelial cells (HUVECs) were
purchased from Cambrex Bio Science (Walkersville, MD).
Cells were cultured in endothelial cell growth medium-2
(EGM-2) and maintained at 37°C in a humidified at-
mosphere containing 5% CO2. HUVECs of passage 2
were used for the experiments.
Cell adhesion assay
Before the adhesion experiments, cells were cultured in
low-serum medium (0.5% FBS) for 12 h and then treated
with resistin (50 ng/mL) for 4 h and labeled with 1, 10-
dioctadecyl-3, 3, 30, 30-tetramethylindocarbocyanine (DiI;
Molecular Probes, Eugene, OR) for 20 min. The labeled
cells (2×105 cells/mL) were added to HUVECs and incu-
bated for 1 h. In parallel experiments, SK-Hep1 cells were
treated with specific inhibitors, neutralizing antibodies, or
transfected with specific siRNAs during resistin stimula-
tion. Non-adherent cells were removed by washing with
























Figure 1 Resistin induced the adhesions of SK-Hep1 cells to
HUVECs. SK-Hep1 cells were kept as CL or treated with resistin at 5,
10, 25 and 50 ng/mL for 4 h. They were then labeled with DiI and
added to confluent monolayers of HUVECs for 1 h. The bar graphs
represent the mean ± standard error of the mean (SEM) from four
independent experiments. *, P < 0.05 vs. control cells.
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scopic fields (1.37 mm×1.07 mm) under a Nikon Ti-E
inverted epifluorescence microscope with ×10 objective,
and the adhesion was expressed as a multiple compared
to the controls.
Real-time quantitative PCR
Real-time PCR of three transcripts was performed using
an ABI Prism 7900HT with the FastStart DNA SYBR
Green I kit (Roche). The designed primers in this study
were: ICAM-1 forward primer, 5′-GTGAC ATGCA
GCACC TCCTG-3′; ICAM-1 reverse primer, 5′-TCCAT
GGTGA TCTCT CCTCA-3′; VCAM-1 forward primer,
5′-CCGGA TTGCT GCTCA GATTG GA-3′; VCAM-1
reverse primer, 5′-AGCGT GGAAT TGGTC CCCTC
A-3′; 18S rRNA forward primer, 5′-CGGCG ACGAC
CCATT CGAAC-3′; 18S rRNA reverse primer, 5′-
GAATC GAACC CTGAT TCCCC GTC-3′. Quantifica-
tion was performed using the 2−ΔΔCt method (30). All
samples were measured in duplicate. The average value
of both duplicates was used as the quantitative value.
ELISA for cell surface ICAM-1 and VCAM-1 expression
ICAM-1 and VCAM-1 expression on the cancer cell sur-
face was measured by cell surface ELISA as previously de-
scribed [23]. Briefly, SK-Hep1 cells cultured in 96-well
plates were fixed by 4% paraformaldehyde. Cell surface
ICAM-1 and VCAM-1 expression were assessed using the
mouse anti-human ICAM-1 or VCAM-1 mAb, followed
by a horseradish-peroxidase-conjugated secondary anti-
body. Cells were then washed with PBS before the
addition of 3,3′,5,5′-tetramethylbenzidine. The reaction
was allowed to develop at room temperature before
A600 determination using a plate reader.
siRNA transfection
For siRNA transfection, SK-Hep1 cells were transfected
with the specific ICAM-1 and VCAM-1-siRNA or control
siRNA by using an RNAiMAX transfection kit (Invitrogen).
Transcription factor assays (TF ELISA assays)
Nuclear extracts of cells were prepared by nuclear pro-
tein extract kits (Panomics, Redwood City, CA). Equal
amounts of nuclear proteins were used for quantitative
measurements of NF-κB p65 activation using commer-
cially available ELISA kits (Panomics).
Statistical analysis
The results are expressed as the mean ± standard error
of the mean (SEM). Statistical analysis was determined
using an independent Student t-test for two groups of
data and analysis of variance (ANOVA) followed by
Scheffe’s test for multiple comparisons. P values less
than 0.05 were considered significant.Results
Resistin induced the adhesions of SK-Hep1 cells to
HUVECs
In order to determine the HCC cancer cell adhesion to
the endothelium, SK-Hep1 cells were kept as the control
or treated with different concentrations of resistin (i.e. 5,
10, 25 and 50 ng/ml) for 4 h and then subsequently
marked with the fluorescent cell tracker DiI to test the
adhesions of cells to HUVECs. The marked cells were
seeded onto the HUVEC monolayers and co-cultured
for 1 h. After removal of the non-adherent cells, the
remaining adherent cells were examined. Treatment
with resistin for 4 h resulted in increased adhesions of
SK-Hep1 cells to HUVECs in a dose-dependent manner
over the range tested, and the induction reached a level
approximately 8 times the untreated control under
50 ng/mL of resistin treatments (Figure 1). Hence, we will
further investigate the following molecular mechanisms of
resistin effects on HCC adhesion to the endothelium by
treating the cells with 50 ng/mL of resistin.
Resistin-induced SK-Hep1 cell adhesions to HUVECs was
inhibited by AMPK
Recently, AMPK, an energy-sensing kinase, was shown
to regulate cancer cell metastasis. Hence, we investigated
whether resistin-increased adhesions of SK-Hep1 cells to
HUVECs are mediated by AMPK. First, SK-Hep1 cells
were pretreated with AICAR, AMPK activator, at different
concentrations (i.e., 0, 0.1, 0.5 and 1 ng/ml) for 1 h and
then kept as the control or treated with resistin (50 ng/mL)
for 4 h, and their adhesions to HUVECs were exam-
ined. Treatment with only resistin increased the SK-Hep1
cell adhesions to HUVECs, which reached a level approxi-
mately 8 times the untreated control. However, pretreat-
ment with AICAR at 0.1, 0.5 and 1 ng/ml resulted in
significant decreases on resistin-induced SK-Hep1 cell
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(Figure 2A). Next, SK-Hep1 cells were pretreated with
AICAR at 0 or 1 ng/mL for 1 h and then kept as the
control or treated with different concentrations of resis-
tin (i.e. 10, 25 and 50 ng/mL) for 4 h. In all three con-
centration doses of resistin, pretreatment with 1 ng/mL
of AICAR inhibited the resistin effects on SK-Hep1 cell
adhesions to HUVECs, compared to treatment with
resistin-only cells (Figure 2B).
Resistin induced both ICAM-1 and VCAM-1 expressions in
SK-Hep1 cells
Because cell adhesion molecules have been shown to be
critical in cancer cell metastasis, we examined the effect
of resistin on the ICAM-1 and VCAM-1 mRNA and cell
surface protein expressions in SK-Hep1 cells. SK-Hep1
cells were kept as the control or treated with resistin
(50 ng/mL) for 1, 2, 4 and 8 h and then analyzed by
real-time PCR for ICAM-1 and VCAM-1 mRNA expres-
sions and ELISA for ICAM-1 and VCAM-1 cell surface
protein expressions. Treatment with resistin for 1, 2, 4 and
8 h induced rapid increases (within 1 h) in the ICAM-1
and VCAM-1 mRNA expressions (Figure 3A and C) and
cell surface protein expressions (Figure 3B and D), which
reached a maximal level compared to the untreated con-
trol within 4 h, and then declined but remained elevated
after 8 h of treatment.
The inhibitions of ICAM-1 and VCAM-1 activity and mRNA
expression in SK-Hep1 cells attenuated their adhesions to
HUVECs
To investigate the roles of ICMA-1 and VCAM-1 in the
adhesions of SK-Hep1 cells to HUVECs, we blocked the
ICAM-1 and VCAM-1 activities by using neutralizing
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Figure 2 Resistin-induced SK-Hep1 cell adhesions to HUVECs were inh
activator, at different concentrations (i.e. 0, 0.1, 0.5 and 1 ng/ml) for 1 h. Th
for 4 h. (B) SK-Hep1 cells were pretreated with AICAR at 0 or 1 ng/mL for
concentrations of resistin (i.e. 10, 25 and 50 ng/mL) for 4 h. The bar graph
*, P < 0.05 vs. control cells. #, P < 0.05 vs. cells treated with resistin only.using ICAM-1- and VCAM-1-specific siRNAs. SK-Hep1
cells were pretreated with IgG, ICAM-1, VCAM-1, or
both neutralizing antibodies. They were then kept as the
control or treated with resistin (50 ng/mL) for 4 h. The
resistin-increased cell adhesions to HUVECs were atten-
uated by ICAM-1 or VCAM-1 single-antibody treatment
as compared to IgG pretreated cells. Treating the cells
with both neutralizing antibodies resulted in enhanced
attenuation effects as compared to single-neutralizing
antibody pretreated cells (Figure 4A). The inhibitions of
resistin-increased SK-Hep1 cell adhesions to HUVECs
by blocking ICAM-1 and VCAM-1 activities were substan-
tiated by transfecting the cells with ICAM-1-, VCAM-1-,
or both specific siRNAs (40nM), which showed the similar
inhibitory effects to the neutralizing antibodies stimula-
tions on resistin-increased SK-Hep1 cell adhesions to
HUVECs (Figure 4B). ICAM-1- and VCAM-1-specific
siRNAs had 70 ~ 80% blocking effects on their respect-
ive protein expressions (data not shown).Resistin-induced ICAM-1 and VCAM-1 expressions were
mediated by AMPK
Next, we determined whether resistin-induced ICAM-1
and VCAM-1 mRNA expressions are mediated through
AMPK in SK-Hep1 cells. SK-Hep1 cells were pretreated
with AICAR at different concentrations (i.e. 0, 0.1, 0.5 and
1 ng/ml) for 1 h and then kept as the control or treated
with resistin (50 ng/mL) for 4 h. Their ICAM-1 and
VCAM-1 mRNA expressions were determined by real-
time PCR. Treatment with only resistin induced ICAM-1
and VCAM-1 mRNA expressions, which reached a level
approximately 8 and 6 times that of the untreated control,
respectively. However, pretreatment with AICAR at
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ibited by AMPK. (A) SK-Hep1 cells were pretreated with AICAR, AMPK
ey were then kept as the control (CL) or treated with resistin (50 ng/mL)
1 h. They were then kept as the control (CL) or treated with different


































































































Figure 3 Resistin induced both ICAM-1 and VCAM-1 expressions in SK-Hep1 cells. SK-Hep1 Cells were kept as the control (CL) or treated
with resistin (50 ng/mL) for 1, 2, 4 and 8 h. They were then analyzed by real-time PCR for ICAM-1 and VCAM-1 mRNA expressions (A and C) and
ELISA for ICAM-1 and VCAM-1 cell surface protein expressions (B and D). The bar graphs represent the mean ± SEM from three independent
experiments. *, P < 0.05 vs. control cells.
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cells (Figure 5).
AMPK attenuates resistin-increased SK-Hep1 cell
adhesions to HUVECs through activating the NF-κB
NF-κB is the most important transcription factor in
modulating cell adhesion molecule expressions, and also
plays a critical role in the resistin-signaling pathway. We
investigated whether the inhibitory effects of AMPK on
resistin-increased SK-Hep1 cell adhesions to HUVECs















































Figure 4 The inhibitions of ICAM-1 and VCAM-1 activity and mRNA e
SK-Hep1 cells were pretreated with IgG, ICAM-1, VCAM-1, or both neutraliz
They were then kept as the control or treated with resistin (50 ng/mL) for 4
experiments. *, P < 0.05 vs. control cells (CL). #, P < 0.05 vs. cells pretreated w
pretreated with ICAM-1 or VCAM-1 single neutralizing antibody or siRNA anthe control or treated with resistin (50 ng/mL) for 1, 2
and 4 h. The NF-κB activations were analyzed by ELISA.
Treating the cells with resistin induced rapid activations
(within 1 h) of NF-κB, which reached a maximal level in
the untreated control within 2 h; it then declined but
remained elevated after 4 h of treatment (Figure 6A).
SK-Hep1 cells were kept as the control or pretreated
with DMSO or NF-κB inhibitors, PDTC (20 μM) or SN50
(50 μg/mL), and then treated with resistin (50 ng/mL) for
4 h. Treating the cells with DMSO/resistin increased the













































xpression in SK-Hep1 cells attenuated their adhesions to HUVECs.
ing antibodies (A) or with ICAM-1, VCAM-1, or both specific siRNA (B).
h. The bar graphs represent the mean ± SEM from three independent
ith IgG or siCL and then treated with resistin only. **, P < 0.05 vs. cells
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Figure 5 Resistin-induced ICAM-1 and VCAM-1 expressions were mediated by AMPK. SK-Hep1 cells were pretreated with AICAR at different
concentrations (i.e. 0, 0.1, 0.5 and 1 ng/ml) for 1 h. They were then kept as the control or treated with resistin (50 ng/mL) for 4 h, and their ICAM-1
(A) and VCAM-1 (B) mRNA expressions were determined by using real-time PCR. The bar graphs represent the mean ± SEM from three
independent experiments. *, P < 0.05 vs. control cells. #, P < 0.05 vs. cells treated with resistin only.
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data. However, both NF-κB inhibitor treatments inhibited
these effects (Figure 6B). Next, SK-Hep1 cells were kept as
the control or pretreated with AICAR at different concen-
trations (i.e. 0, 0.1, 0.5 and 1 ng/ml) for 1 h and then
treated with resistin (50 ng/mL) for 4 h, and NF-κB activ-
ity was determined by ELISA. Treatment with only resistin
induced NF-κB activations, which reached a level approxi-
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Figure 6 AMPK attenuated resistin-increased SK-Hep1 cell adhesions
kept as the control or treated with resistin (50 ng/mL) for 1, 2 and 4 h. (B)
inhibitors, PDTC or SN50, to inhibit activity. They were then treated with re
pretreated with AICAR at different concentrations (i.e. 0, 0.1, 0.5 and 1 ng/m
for 4 h. (D) SK-Hep1 cells were treated with resistin (50 ng/mL) or AICAR at di
control cells. #, P < 0.05 vs. cells treated with resistin only.pretreatment with AICAR at 0.1, 0.5 and 1 ng/ml resulted
in significant inhibitions of NF-κB activations in SK-Hep1
cells (Figure 6C). Treatment with AICAR alone at 0.1, 0.5
and 1 ng/ml has no effect on NF-κB activations (compared
to untreated control) in SK-Hep1 cells (Figure 6D).
Discussion
The aim of the present study was to investigate the role
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to HUVECs through activating the NF-κB. (A) SK-Hep1 cells were
SK-Hep1 cells were kept as the control pretreated with DMSO or NF-κB
sistin (50 ng/mL) for 4 h. (C) SK-Hep1 cells were kept as the control or
l) for 1 h and then kept as the control or treated with resistin (50 ng/mL)
fferent concentrations (i.e. 0, 0.1, 0.5 and 1 ng/ml) for 4 h. *, P < 0.05 vs.
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systematic studies, we have characterized the mechanisms
by which resistin regulates the SK-Hep1 cell adhesion to
the endothelium through ICAM-1 and VCAM-1 ex-
pressions in SK-Hep1 cells; we have found that AMPK
activation serves as an antagonist to attenuate this
effect. These conclusions were based on the following
results: (i) Resistin increases the SK-Hep1 cell adhesion
to HUVECs. However, AMPK activation in SK-Hep1
significantly attenuates this resistin effect. (ii) Resistin-
increased SK-Hep1 cell adhesions to HUVECs occur
through the induction of ICAM-1 and VCAM-1 mRNA
and cell surface protein expressions in SK-Hep1 cells.
(iii) AMPK activation-attenuated resistin effects on SK-
Hep1 cell adhesion to HUVECs are through inhibiting
NF-κB activity and following ICAM- and VCAM-1
expressions. Thus, our findings provide insights into the
molecular mechanisms by which resistin regulates HCC
adhesion to the endothelium in SK-Hep1 cells.
Increasing epidemiological evidence has demonstrated
that obesity is associated with a range of cancer types,
including HCC [5-8]. In addition to regulate the metabolic
homeostasis within the adipose tissue, adipocyte-secreted
adipokines have also been indicated to play important role
both in cancer risk and cancer mortality [11]. Our study
has shown that resistin induces SK-Hep1 cell adhesion to
the endothelial cells. Recently, resistin has been impli-
cated to serve as a marker of diagnosis and prognosis in
different types of cancer. Lee et al. and Dalamaga et al.
indicated that resistin expressions in breast cancer tissues
are associated with patient clinicopathological variables
[10,24]. Danese et al. clarified that the serum resistin levels
are significantly higher in colorectal cancer patients than
in healthy controls [1]. However, the precise roles of
resistin on cancer development are still unclear. In the
present study, we have demonstrated that (a) resistin
has no inhibitory effects on the viability of SK-Hep1
cells (see Additional file 1) and (b) resistin has capability
to induce the adhesion of SK-Hep1 cell to the endothe-
lial cells and hence we have speculated that resistin
might be an important mediator for initiating the HCC
metastasis.
The adhesion of cancer cell to the vascular endothelium
is a critical step to result in the cancer cell metastasis
[25,26]. The expressions of adhesion molecules, including
ICAM-1 and VCAM-1, in endothelial cells have been
shown to play important roles to mediate this metastatic
process [26]. However, our study has shown that resistin
induces both ICAM-1 and VCAM-1 expressions in SK-
Hep1 cells. Recent studies have indicated that the serum
ICAM-1 and/or VCAM-1 are increased in HCC, breast
and colorectal cancer [27-31]. However, it has been shown
that these elevated adhesion molecules expressions in pa-
tients are associated with advanced diseases and mightcontribute prognostic significance in patients. Our study
further demonstrated that the role of both ICAM-1 and
VCAM-1 in the SK-Hep1 cells is to promote the SK-Hep1
cell adhesion to the endothelial cells under resistin
stimulation. The receptors of ICAM-1 and VCAM-1 are
the LFA-1 and VLA4 integrins, respectively, and they
are only express in the immune cells, including the leu-
kocytes [32]. Moreover, the elevated soluble serum
ICMA-1 and VCAM-1 in patients have also been shown
to be associated with the inflammatory reactions within
tissues [27-31]. Recently novel metastatic theory has in-
dicated that the cancer cell-leukocyte fusion play poten-
tial role in the cancer metastasis [33]. Therefore, the
issue about whether resistin-induced HCC adhesion to
the endothelium through ICAM-and VCAM-1 in HCC
is regulated by leukocytes warrants further exploration.
AMPK is known to be an energy sensor that controls
the cellular metabolisms in normal cells [34-38]. How-
ever, it has also been indicated that AMPK is a novel
therapeutic target for cancer and metabolic diseases
[39-41]. Our study has shown that AMPK activation at-
tenuates the resistin-increased SK-Hep1 cell adhesion to
the endothelial cells. This data is supporting by recent
discoveries that AMPK activation play a critical role in
inhibiting cancer metastasis: (a) Taliaferro-Smith et al.
demonstrated that AMPK activation by adiponectin in-
hibits the migration of breast cancer cells [42]; (b) Kin
et al. indicated that berberine increases AMPK activity
and hence decreases the migration of melanoma cells [20];
(c) Park et al. also demonstrated that berberine inhibits
colon cancer migration by activating AMPK [21]. The in-
hibitory effects of AMPK activation on resistin-induced
SK-Hep1 cell adhesion in our study are through adding
the AMPK agonist, AICAR. Recent study has shown that
resistin inhibit the AMPK phosphorylation to modulate
glucose metabolism in human hepatoma cells. Thus, in
our study, whether resistin-induced the SK-Hep1 cell ad-
hesion to the endothelial cells is through inhibiting AMPK
phosphorylation and activation remains to be determined.
In brief, the identification of AMPK activators may be
a promising strategy for the development of novel
therapeutic drugs for cancer metastasis.
Conclusion
Our present study has demonstrated that resistin increases
SK-Hep1 cell adhesion to the endothelial cells, with con-
comitant increases in NFκB activity and ICAM-1 and
VCAM-1 mRNA, as well as cell surface protein expres-
sions in SK-Hep1 cells. However, these resistin-increased
responses are attenuated by AMPK activation. Our find-
ings provide a notion that resistin play an important role
in modulating HCC adhesions and suggest AMPK may be
a promising target for a therapeutic intervention against
HCC metastasis.
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Additional file 1: Effect of resistin on cell viability of SK-Hep1.
(A) Cells were kept as controls (CL) or stimulated with resistin at the
indicated time periods. Cell viability was assayed by the MTT test. Bar
graphs represent folds of CL cells, mean ± standard error of the mean
(SEM). *P < 0.05 versus CL.
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